It would be a shame to see further weakness due to the...

It would be a shame to see further weakness due to the comparison of PET and EVS, although I appreciate the risk given the lack of visibility by small shareholders, i.e. how much power do different directors have and how is this changing due to the events which are unfolding over at PET. However, I do see the material risk to the EVS business (rather than simply the share price) as less severe than what has occurred at PET - that being less exposure to China and less direct involvement by ZZL's Director (Non-Exec vs Deputy Chair). Further, I think as a whole the market is placing less valuation on Chinese opportunity due to external factors, therefore part of the drop from the late 2019 entering China hype probably happened back in Feb/Mar. To me it would seem further dips would be short lived and based on (negative) hype, just painful to go through and have to contemplate the what-ifs. Although, as I said at the start, hard to know as a small shareholder - just my opinion (DOYR and form your own).

Thanks for all the commentary though - I only just signed up and came looking today for an explanation of the recent weakness - and I found it - I could then form my own opinion to the risk/reward stemming from that.